<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00371371</url>
  </required_header>
  <id_info>
    <org_study_id>JUVENTAS</org_study_id>
    <secondary_id>06/030</secondary_id>
    <secondary_id>CS 06.007</secondary_id>
    <nct_id>NCT00371371</nct_id>
  </id_info>
  <brief_title>Intra-arterial Stem Cell Therapy for Patients With Chronic Limb Ischemia (CLI)</brief_title>
  <acronym>JUVENTAS</acronym>
  <official_title>Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Patients With Chronic Critical Limb Ischemia: a Randomized, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Catharijne Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to determine whether intra-arterial injection of autologous
      stem cells is effective in the treatment of chronic limb ischemia (CLI), to characterize stem
      cell dysfunction in patients with CLI, and to relate the stem cell function with clinical
      outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite advances in surgical and radiological vascular techniques, a significant number of
      patients with chronic critical limb ischaemia (CLI) are not eligible for revascularization
      procedures, often leaving amputation as the only option. Consequently, exploring new
      strategies for revascularization of ischemic limbs is of major importance. Preclinical
      studies and pioneering clinical trials suggest that administration of bone marrow (BM)
      mononuclear cells (MNC) into ischemic limbs enhances neovascularization, improves tissue
      perfusion and prevents amputation. However, no definite proof is available as the clinical
      studies thus far have been small and lacked double-blinded controls.

      JUVENTAS is a randomized, double-blinded placebo-controlled trial in 109 - 160 patients with
      CLI to investigate the potential clinical effects of repeated intra-arterial infusion of
      BM-MNC in these patients (the exact number of patients to be included cannot be specified in
      advance because of the planned group sequential interim analyses). In addition, it will study
      the functional characteristics of the BM-MNC obtained from CLI patients and relate BM-MNC
      dysfunction to clinical outcome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>major amputation</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>minor amputation</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number and extent of leg ulcers</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resolvement of rest pain</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement of ankle-brachial index (ABI)</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement transcutaneous oxygen pressure (TcpO2)</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in quality of life</measure>
    <time_frame>suix months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in clinical status (Rutherford classification)</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Amputation-free survival</measure>
    <time_frame>six months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Treatment failure</measure>
    <time_frame>six months</time_frame>
    <description>Composite endpoint defined as major amputation of treated leg, all-cause mortality, doubling in total wound surface area, or de novo gangrene</description>
  </other_outcome>
  <other_outcome>
    <measure>Successfull treatment</measure>
    <time_frame>six months</time_frame>
    <description>Composite endpoint defined as subject is (A) alive, (B) without major amputation of index limb, (C) not worsened rutherford class or VAS, and (D) improved in either Rutherford or VAS (&gt;30mm)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Peripheral Vascular Diseases</condition>
  <condition>Arterial Occlusive Diseases</condition>
  <condition>Leg Ulcer</condition>
  <condition>Gangrene</condition>
  <condition>Ischemia</condition>
  <arm_group>
    <arm_group_label>BM-MNC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologous bone marrow-derived mononuclear cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow punction</intervention_name>
    <description>A total volume of 100 ml bone marrow will be aspirated from the iliac crest under local anaesthesia (lidocaine) according to local routine. To maximise the patients comfort, 5-10 mg midazolam and 50 ug fentanyl will be administered intravenously.</description>
    <arm_group_label>BM-MNC</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>BM-MNC infusion</intervention_name>
    <description>Repeated intra-arterial infusion of autologous BM-MNC into the common femoral artery</description>
    <arm_group_label>BM-MNC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placebo infusion</intervention_name>
    <description>Repeated intra-arterial infusion of placebo (PBS/4% HAS/heparin, coloured with autologous erythrocytes to match the colour of BM-MNC suspension) into the common femoral artery.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Severe infra-popliteal peripheral arterial occlusive disease [PAOD] (Fontaine class
             IIb, III or IV)

          -  Invalidating intermittent claudication, persistent, recurring rest pain requiring
             analgesia and/or non-healing ulcers present for &gt; 4 weeks without evidence of
             improvement in response to conventional therapies

          -  Ankle brachial index &lt; 0.6 or &quot;unreliable&quot;

          -  Not eligible for surgical or radiological revascularization

          -  Written informed consent

        Exclusion Criteria:

          -  History of neoplasm or malignancy in the past 10 years

          -  Serious known concomitant disease with life expectancy of less than one year

          -  Anticipated inability to obtain 100 ml of bone marrow aspirate

          -  Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C
             virus

          -  Follow-up impossible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frans L Moll, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marianne C Verhaar, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ralf W Sprengers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Teraa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Utrecht (UMC Utrecht)</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Sprengers RW, Lips DJ, Moll FL, Verhaar MC. Progenitor cell therapy in patients with critical limb ischemia without surgical options. Ann Surg. 2008 Mar;247(3):411-20. doi: 10.1097/SLA.0b013e318153fdcb. Review.</citation>
    <PMID>18376183</PMID>
  </reference>
  <reference>
    <citation>Sprengers RW, Janssen KJ, Moll FL, Verhaar MC, van der Graaf Y; SMART Study Group. Prediction rule for cardiovascular events and mortality in peripheral arterial disease patients: data from the prospective Second Manifestations of ARTerial disease (SMART) cohort study. J Vasc Surg. 2009 Dec;50(6):1369-76. doi: 10.1016/j.jvs.2009.07.095. Epub 2009 Oct 17.</citation>
    <PMID>19837547</PMID>
  </reference>
  <reference>
    <citation>Sprengers RW, Moll FL, Verhaar MC. Stem cell therapy in PAD. Eur J Vasc Endovasc Surg. 2010 Mar;39 Suppl 1:S38-43. doi: 10.1016/j.ejvs.2009.12.001. Epub 2010 Feb 12.</citation>
    <PMID>20153223</PMID>
  </reference>
  <reference>
    <citation>Sprengers RW, Moll FL, Teraa M, Verhaar MC; JUVENTAS Study Group. Rationale and design of the JUVENTAS trial for repeated intra-arterial infusion of autologous bone marrow-derived mononuclear cells in patients with critical limb ischemia. J Vasc Surg. 2010 Jun;51(6):1564-8. doi: 10.1016/j.jvs.2010.02.020.</citation>
    <PMID>20488328</PMID>
  </reference>
  <reference>
    <citation>Sprengers RW, Teraa M, Moll FL, de Wit GA, van der Graaf Y, Verhaar MC; JUVENTAS Study Group; SMART Study Group. Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment. J Vasc Surg. 2010 Oct;52(4):843-9, 849.e1. doi: 10.1016/j.jvs.2010.04.057.</citation>
    <PMID>20598482</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2006</study_first_submitted>
  <study_first_submitted_qc>September 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2006</study_first_posted>
  <last_update_submitted>December 12, 2012</last_update_submitted>
  <last_update_submitted_qc>December 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>R.W. Sprengers, MD, PhD</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>clinical trial</keyword>
  <keyword>chronic critical limb ischemia</keyword>
  <keyword>leg pain</keyword>
  <keyword>cell therapy</keyword>
  <keyword>bone marrow</keyword>
  <keyword>mononuclear</keyword>
  <keyword>progenitor cell</keyword>
  <keyword>stem cell</keyword>
  <keyword>critical limb ischemia</keyword>
  <keyword>nonhealing leg ulcer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
    <mesh_term>Gangrene</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

